GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Forward PE Ratio

Biotest AG (Biotest AG) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Forward PE Ratio?

Biotest AG's Forward PE Ratio for today is 0.00.

Biotest AG's PE Ratio without NRI for today is 8.03.

Biotest AG's PE Ratio for today is 8.03.


Biotest AG Forward PE Ratio Historical Data

The historical data trend for Biotest AG's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Forward PE Ratio Chart

Biotest AG Annual Data
Trend 2021-12 2022-03
Forward PE Ratio
476.19 476.19

Biotest AG Quarterly Data
2021-09 2021-12 2022-03
Forward PE Ratio 416.67 476.19 476.19

Competitive Comparison of Biotest AG's Forward PE Ratio

For the Biotechnology subindustry, Biotest AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Biotest AG's Forward PE Ratio falls into.



Biotest AG Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Biotest AG  (OTCPK:BIESF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Biotest AG Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Biotest AG's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024